NRX Pharmaceuticals, Inc.: 10-Q filed 2019-11-14
What NRX Pharmaceuticals, Inc. reported in its quarterly report filed 2019-11-14 (fiscal Q3 2019): 19 published measures, 62 facts as tagged in accession 0001654954-19-012962.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-11-14
- Fiscal period
- fiscal Q3 2019
- Accession
- 0001654954-19-012962 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NRX Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 41,685,076 | USD | |
| At 2018-12-31 | 70,796,159 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 2,433,757 | USD | |
| At 2018-12-31 | 1,257,410 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 5,000,006 | USD | |
| At 2019-06-30 | 5,000,008 | USD | |
| At 2019-03-31 | 5,000,005 | USD | |
| At 2018-12-31 | 5,000,006 | USD | |
| At 2018-09-30 | 5,000,009 | USD | |
| At 2018-06-30 | 5,000,009 | USD | |
| At 2018-03-31 | 5,000,005 | USD | |
| At 2017-12-31 | 5,000,001 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 59,195 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 423,181 | USD | 273 |
| 2019-04-01 to 2019-06-30 | 176,021 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 187,965 | USD | 90 |
| 2018-07-01 to 2018-09-30 | 28,084 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 36,962 | USD | 273 |
| 2018-04-01 to 2018-06-30 | -6,602 | USD | 91 |
| 2018-01-01 to 2018-03-31 | 15,481 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -530,657 | USD | 273 |
| 2018-01-01 to 2018-09-30 | -402,303 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -29,888,599 | USD | 273 |
| 2018-01-01 to 2018-09-30 | -7,500 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 30,602,457 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 37,515 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 384,249 | USD | |
| At 2018-12-31 | -38,932 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 15,736 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 88,128 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 34,989 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 48,052 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -183,305 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -522,228 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -220,243 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -684,427 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 208,030 | USD | |
| At 2018-12-31 | 30,193 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 641,745 | USD | |
| At 2018-12-31 | 567,410 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 30,990,611 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 0 | USD | 273 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 183,305 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 522,228 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 220,243 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 684,427 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 2,810,261 | shares | |
| At 2018-12-31 | 2,725,039 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 4,612,947 | USD | |
| At 2018-12-31 | 5,036,213 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 74,931 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 511,309 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 63,073 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 85,014 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -100,291 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -235,815 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -160,159 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -505,764 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 258,236 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 1,033,537 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 283,316 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 769,441 | USD | 273 |
Inspect the source
- Entity
- NRX Pharmaceuticals, Inc. / CIK 0001719406
- Captured
- 2026-09-21T17:27:10.215Z
- SEC response SHA-256
6397c43beff03c5cfffaefec8f7831ab311854b7252e2db1d5c35f1cb8b83bdf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001719406.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))